Compare TJX Companies Inc (TJX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TJX Companies Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? TJX Companies Inc trades at $155 (market cap $172.00B), while Vertex Pharmaceuticals Incorporated trades at $481.09 (market cap $121.95B). The key difference: TJX Companies Inc is the larger of the two by market cap, and TJX Companies Inc pays a 1.23% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| TJX | VRTX | |
|---|---|---|
Market Cap | $172.00B | $121.95B |
Sector | Consumer Cyclical | Health |
52-Week High | $168.41 | $529.59 |
52-Week Low | $124.53 | $366.54 |
Enterprise Value | $180.60B | $116.69B |
Dividend Yield | 1.23% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
